Cargando…
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
Autores principales: | Beird, Hannah, Yin, C. Cameron, Khoury, Joseph D., Pierce, Sherry, Abbas, Hussein A., Zhao, Li, Skwarska, Anna, Qazilbash, Muzaffar, Konopleva, Marina, Futreal, P. Andrew, Pemmaraju, Naveen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188632/ https://www.ncbi.nlm.nih.gov/pubmed/36689729 http://dx.doi.org/10.1182/bloodadvances.2022007879 |
Ejemplares similares
-
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
por: Beird, Hannah C., et al.
Publicado: (2019) -
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
por: Pemmaraju, Naveen, et al.
Publicado: (2022) -
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Yin, C. Cameron, et al.
Publicado: (2021) -
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm
por: Economides, Minas P., et al.
Publicado: (2019) -
Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)